Update on Anxiolytics and Hypnotics Lynn Osako University of California, San Francisco

Total Page:16

File Type:pdf, Size:1020Kb

Update on Anxiolytics and Hypnotics Lynn Osako University of California, San Francisco Chapman University Chapman University Digital Commons Pharmacy Faculty Articles and Research School of Pharmacy 1992 Update on Anxiolytics and Hypnotics Lynn Osako University of California, San Francisco Mary Gutierrez Chapman University, [email protected] Michael Z. Wincor University of Southern California Follow this and additional works at: http://digitalcommons.chapman.edu/pharmacy_articles Recommended Citation Osako L, Gutierrez MA, Wincor M. Update on anxiolytics and hypnotics. Calif Pharmacist. 1992:32-37. This Article is brought to you for free and open access by the School of Pharmacy at Chapman University Digital Commons. It has been accepted for inclusion in Pharmacy Faculty Articles and Research by an authorized administrator of Chapman University Digital Commons. For more information, please contact [email protected]. Update on Anxiolytics and Hypnotics Comments This article was originally published in California Pharmacist in 1992. Copyright California Pharmacists Association This article is available at Chapman University Digital Commons: http://digitalcommons.chapman.edu/pharmacy_articles/488 "' JOURNAL CE------------------------------------------~ • Lynn Osako, Pharm.D, History Mary Gutierrez, Pharm.D. and Michael Wincor, Pharm.D. Agents to produce sleep, called hypnotics, have been around thousands of yeats. Evidence shows that poppy plants were used as the first hypnotics sorne two-thousand yeats ago. The old­ est hypnotic agent is chloral hydrate. Its popularity waned when the barbiturates came along but has become more popu­ lar in the last few decades. 1 It is less effective than flurazepam and tolerance toits effects develops rapidly.2 The bromides were introduced in the mid-1800s. Problems with these agents Update on include the ir extremely long half-life of about 12 days, their low therapeutic in­ dex and irritation to the Gl system.1 anxiolytics and Early in the 20th century, barbitu­ rates were introduced and quickly be­ came popular hypnotic agents. These hypnotics agents have numerous adverse reactions such as respiratory depression, nausea and vomiting, circulatory collapse and severe depression of the CNS. Barbitu­ rates have become associa red with abuse and overdose, and drug withdrawal can also be a serious problem. A chronic user of barbiturates, upon withdrawal, may Goal experience irritability, insomnia and, in serious cases, convulsions and death.1 The goal of this article is to educate pharmacists on the new er anxiolytic and hypnotic agents. Other nonbarbiturate-nonbenzo­ diazepines indude piperidinediones su ch Objectives as glutethimide and methyprylon, ethchlorvynol, methaqualone and mep­ After reading this article, the pharmacist shouid be able to: robamate. Ali of these agents have prob­ lems similar to those of the barbiturates, • Discuss the advantages of the new hypnotics and anxiolytics over specifically physical dependence and 1 3 previous agents. overdose potential. • • Discuss possible adverse effects and drug interactions of the new Benzodiazepines were a major break­ hypnotics and anxiolytics. through in sedative-hypnotics and have become the most frequently prescribed • Recommend one of the newer agents as an alternative to more conven­ drugs in the U.S. Their main advantage tionai therapy when appropriate. over previous agents are their higher therapeutic index. T aken alone, these agents rarely cause death and produce 1 3 Provided by an educational grant from little respiratory depression. • Physical dependence has become their major problem, however. 1 Drug therapies of anxiety states are a 32 • CALIFORNIA PHARMACIST • NOVEMBER 1992 JOURNAL CE fairly recent development. Although hypertensive crisis, which can occur epines in itschemical and pharmacologie anxiety states were recognized in the when the patient on an MAOI eats food properties. It was first introduced in 1985 19th cenrury, most therapy revolved rich in tyramine (aged cheese, red wine, in West Germany and is the first drug around psychotherapy.4 A variety of sherry, beer, smoked meats orfish, etc.) developed primarily as an anxiolytic.4 drugs in different pharmacological classes and uses sympathomimetics or stimu­ are now used to treat the anxiety disor­ lants. Another disadvantage is that it Pharmacology. Unlike the benzodi­ ders. Alcohol is commonly used to self­ takes weeks for a noticeable effect to azepines, buspirone actually increases rreat situational anxiety; however, it is occur.5 noradrenergic activity. Buspirone's never a treatment of choice, 5 and alco­ mechanism of action is not completely holism has become a complication of lmipramine is the tricyclic amide­ understood, but it apparently does not many anxiety disorders. z pressant (TCA) most commonly used involve action on the benzodiazepine­ for treating panic disorder, while other gamma aminobutyric acid-chloride ( BZ­ 1 When barbiturates came along, they TCAs su ch as desipramine are occasion­ GABA-Cl) ionophore camp lex. It binds were not only used as hypnotics, but also ally used.5 Like the MAOis, weeks of selectively ta 5-HT lA receptors, and this used to treat anxiety.2 Barbiturates are therapy are required before a response is most likely where the majority of its not, however, specifie anxiolytics and occurs. Their anticholinergic side ef­ have the disadvantages discussed ear­ fects are more pronounced than with the Her. MAOls and may cause psychotic reac­ 2 5 • tions, especially in the elderly. • TCAs Antihistamines are used occasionally can also cause orthostatic hypotension, The major and are especially good for patients with tachycardia and decreased cardiac con­ 5 6 2 5 a high propensity for drug abuse. • The duction. • T oxicity is another serious disadvantage for ali anticholinergic effects of these agents problem with these patients, and a few the hypnotics and for are their primary disadvantage, espe· week's supply can easily cause death. cîally in the elderly in whom central most of the anxiolytics effects such as confusion and hallucina­ Benzodiazepines, as mentioned car­ is their potential for tions may also occur.5 lier, are the most commonly prescribed drugs in the U.S. Anxiery syndromes physical dependence. Beta-adrenergic blocking agents are make up a large percentage of those For those anxiolytics used primarily to alleviate the physical prescriptions, and benzodiazepines can symptoms of stress. These agents are be used in ali different types of anxiety without addictive nonspecific and rarely are helpful in disorders. Their advantages and disad­ potential, the primary psychiatrie patients.4 Clonidine is also vantages are mentioned above in the used to treat anxiety; however, its side discussion on hypnotics. problems are adverse effects of hypotension, depression and effects and toxicity. fatigue have limited its use.5 The need for newer agents Antipsychotics were used more fre­ Although the above-mentioned quently for anxiety attacks in the past. agents are effective against anxiety and They are less commonly used for thar insomnia, each has its own problems. anxiolytic activity is produced. 7 These purpose now because of their question­ The major disadvantage for all the receptors are localized in areas of the able efficacy and the ir high potential for hypnotics and for most of the anxiolytics CNS which may explain its more favor­ adverse effects su ch as tardive dyskinesia is their potential for physical depen­ able adverse effect profile versus the and extrapyramidal effects. 4•6 dence. For those anxiolytics without benzodiazepines. Buspirone does not addictive potential, the primary prob­ share the anticonvulsant and muscle Antidepressants, however, continue lems are adverse effects and toxicity. relaxant properties of the benzodiaz­ to be used and have shawn efficacy in Therefore, the search goes on for drugs epines and exhibits anxiolytic effects certain anxiety states. In the early 1960s with specifie actions, few side effects, a only.7 monamine oxidase inhibitors (MAOls) high therapeutic index and no addictive were found to be effective for panic potential. Pharmacokinetics. Buspirone is ab­ disorder.6 Phenelzine is most commonly sorbed rapidly and completely from the used, and studies have proven its effec­ Buspirone (Buspar®) 01 system. After undergoing first-pass tiveness in panic disorder.5 Side effects metabolism only 4% of the drug reaches include orthostatic hypotension, weight Buspirone is a relatively new drug the systemic circulation.5 The onset of gain, sexual dysfunction, edema and which is unique from the beruodiaz- action of buspirone is considerably de- NOVEMBER 1992 • CALIFORNIA PHARMACIST • 33 JOURNAL CE--------------------------------------------~ layed and occurs sometime during the should be a 10-day washout after MA01 This is probably due to its long onset of first three weeks of therapy; therefore, it use before buspirone therapy is initi­ action and because buspirone does not cannat be used for short-term or as­ ated. 8 There have be en reports of eleva­ alleviate the withdrawal symptoms of needed treatment. The distribution of tions in ALT concentrations with con­ benzodiazepines. buspirone is not completely known. The comitant buspirone and trazodone use. apparent volume of distribution is about However, this remains unconfirmed in Dosing and administration. 5.3 L/kgJ It is 95% bound to plasma studies. As long as liver function tests Buspirone is only available orally. The proteins,5 mostly to albumin and a 1- are monitored, the manufacturer daims starting dose is 10-15
Recommended publications
  • Insomnia and Anxiety in Older People Sleeping Pills Are Usually Not the Best Solution
    ® Insomnia and anxiety in older people Sleeping pills are usually not the best solution lmost one-third of older people in the people who take one of United States take sleeping pills. These these medicines sleep medicines are also sometimes called only a little longer and A“sedative-hypnotics” or “tranquilizers.” They better than those who affect the brain and spinal cord. don’t take a medicine. Doctors prescribe some of these medicines Sleeping pills can for sleep problems. Some of these medicines have serious side effects. also can be used to treat other conditions, such All sedative-hypnotic medicines have special as anxiety or alcohol withdrawal. Sometimes, risks for older adults. Seniors are likely to be doctors also prescribe certain anti-depressants more sensitive to the medicines’ effects than for sleep, even though that’s not what they’re younger adults. And these medicines may designed to treat. stay in older people’s bodies longer. These Most older adults should first try to treat their medicines can cause confusion and memory insomnia without medicines. According to the problems that: American Geriatrics Society, there are safer and • Increase the risk of falls and hip fractures. better ways to improve sleep or reduce anxiety. These are common causes of hospital stays Here’s why: and death in older people. Sleeping pills may not help much. • Increase the risk of car accidents. Many ads say that sleeping pills help people get a full, restful night’s sleep. But studies show that this is not exactly true in real life. On average, The new “Z” medicines also have risks.
    [Show full text]
  • Drug & Alcohol Testing Program
    Pottawattmie County Drug & Alcohol Testing Program Appendix A Table of Contents POLICY STATEMENT ...................................................................................................................................... 3 SCOPE ............................................................................................................................................................ 4 EDUCATION AND TRAINING .......................................................................................................................... 4 DESIGNATED EMPLOYER REPRESENTATIVE (DER): ....................................................................................... 5 DUTY TO COOPERATE ................................................................................................................................... 5 EMPLOYEE ADMISSION OF ALCOHOL AND CONTROLLED SUBSTANCE USE: (49 CFR Part 382.121) ... 6 PROHIBITED DRUGS AND ILLEGALLY USED CONTROLLED SUBSTANCES: ..................................................... 7 PROHIBITED BEHAVIOR AND CONDUCT: ...................................................................................................... 8 DRUG & ALCOHOL TESTING REQUIREMENTS (49 CFR, Part 40 & 382) ............................................... 10 DRUG & ALCOHOL TESTING CIRCUMSTANCES (49 CFR Part 40 & 382) .............................................. 12 A. Pre-Employment Testing: .................................................................................................... 12 B. Reasonable Suspicion Testing: .........................................................................................
    [Show full text]
  • Early Morning Insomnia, Daytime Anxiety, and Organic Mental Disorder Associated with Triazolam
    Early Morning Insomnia, Daytime Anxiety, and Organic Mental Disorder Associated with Triazolam Tjiauw-Ling Tan, MD, Edward 0. Bixler, PhD, Anthony Kales, MD, Roger J. Cadieux, MD, and Amy L. Goodman, MD Hershey, Pennsylvania A psychiatric syndrome characterized by agita­ Sleep Disorders Clinic. He began taking triazolam tion, paranoid ideation, depersonalization, and de­ at bedtime in a 0.5-mg dose eight months before pression, as well as paresthesias and hyperacusis, his referral. Although the drug was effective ini­ has been attributed to administration of triazolam tially, tolerance developed, causing the patient to (Halcion).1 The occurrence of these reactions led gradually increase the dosage until eventually he to the removal of the drug from the market in the was taking a total of 1.5 mg nightly. Netherlands. Isolated behavioral side effects that The physical examination revealed no contribu­ include amnesia2-4 and hallucinations5 have also tory conditions. However, assessment of the pa­ been reported with administration of triazolam. tient’s mental status revealed that he was extreme­ Rebound insomnia6 and early morning insom­ ly guarded and suspicious and preoccupied with nia,7 both associated with increases in daytime his sleeplessness to the degree that this hypochon­ anxiety,7,8 are withdrawal syndromes known driacal concern had a delusional quality. He also to occur with rapidly eliminated benzodiazepine described two episodes indicating memory impair­ hypnotics such as triazolam. Rebound insomnia ment; both incidents occurred in the late afternoon consists of a marked increase in wakefulness and involved preparing to eat certain foods, which above baseline levels following drug withdrawal.
    [Show full text]
  • MEDICATION GUIDE Estazolam (Es-TAZE-Oh-Lam)
    MEDICATION GUIDE Estazolam (es-TAZE-oh-lam) Tablets, C-IV What is the most important information I should know about estazolam? • Estazolam is a benzodiazepine medicine. Taking benzodiazepines with opioid medicines, alcohol, or other central nervous system depressants (including street drugs) can cause severe drowsiness, breathing problems (respiratory depression), coma and death. • After taking estazolam, you may get up out of bed while not being fully awake and do an activity that you do not know you are doing. The next morning, you may not remember that you did anything during the night. You have a higher chance for doing these activities if you drink alcohol or take other medicines that make you sleepy with estazolam. Reported activities include: ◦ driving a car ("sleep-driving") ◦ making and eating food ◦ talking on the phone ◦ having sex ◦ sleep-walking Call your healthcare provider right away if you find out that you have done any of the above activities after taking estazolam. • Do not take estazolam unless you are able to stay in bed a full night (7 to 8 hours) before you must be active again. • Do not take more estazolam than prescribed. What is estazolam? • Estazolam is a prescription medicine used short-term to treat certain types of insomnia including difficulty falling asleep, waking up often during the night, or waking up early in the morning. • Estazolam is a federal controlled substance (C-IV) because it can be abused or lead to dependence. Keep estazolam in a safe place to prevent misuse and abuse. Selling or giving away estazolam may harm others, and is against the law.
    [Show full text]
  • Comparison of Short-And Long-Acting Benzodiazepine-Receptor Agonists
    J Pharmacol Sci 107, 277 – 284 (2008)3 Journal of Pharmacological Sciences ©2008 The Japanese Pharmacological Society Full Paper Comparison of Short- and Long-Acting Benzodiazepine-Receptor Agonists With Different Receptor Selectivity on Motor Coordination and Muscle Relaxation Following Thiopental-Induced Anesthesia in Mice Mamoru Tanaka1, Katsuya Suemaru1,2,*, Shinichi Watanabe1, Ranji Cui2, Bingjin Li2, and Hiroaki Araki1,2 1Division of Pharmacy, Ehime University Hospital, Shitsukawa, Toon, Ehime 791-0295, Japan 2Department of Clinical Pharmacology and Pharmacy, Neuroscience, Ehime University Graduate School of Medicine, Shitsukawa, Toon, Ehime 791-0295, Japan Received November 7, 2007; Accepted May 15, 2008 Abstract. In this study, we compared the effects of Type I benzodiazepine receptor–selective agonists (zolpidem, quazepam) and Type I/II non-selective agonists (zopiclone, triazolam, nitrazepam) with either an ultra-short action (zolpidem, zopiclone, triazolam) or long action (quazepam, nitrazepam) on motor coordination (rota-rod test) and muscle relaxation (traction test) following the recovery from thiopental-induced anesthesia (20 mg/kg) in ddY mice. Zolpidem (3 mg/kg), zopiclone (6 mg/kg), and triazolam (0.3 mg/kg) similarly caused an approximately 2-fold prolongation of the thiopental-induced anesthesia. Nitrazepam (1 mg/kg) and quazepam (3 mg/kg) showed a 6- or 10-fold prolongation of the anesthesia, respectively. Zolpidem and zopiclone had no effect on the rota-rod and traction test. Moreover, zolpidem did not affect motor coordination and caused no muscle relaxation following the recovery from the thiopental-induced anesthesia. However, zopiclone significantly impaired the motor coordination at the beginning of the recovery. Triazolam significantly impaired the motor coordination and muscle relaxant activity by itself, and these impairments were markedly exacerbated after the recovery from anesthesia.
    [Show full text]
  • Pneumonia Risk Associated with the Use of Individual Benzodiazepines and Benzodiazepine Related Drugs Among the Elderly with Parkinson’S Disease
    International Journal of Environmental Research and Public Health Article Pneumonia Risk Associated with the Use of Individual Benzodiazepines and Benzodiazepine Related Drugs among the Elderly with Parkinson’s Disease Kuang-Hua Huang 1,† , Chih-Jaan Tai 2,3,†, Yu-Hsiang Kuan 4,5 , Yu-Chia Chang 6,7,8, Tung-Han Tsai 1 and Chien-Ying Lee 4,5,* 1 Department of Health Services Administration, China Medical University, Taichung 40402, Taiwan; [email protected] (K.-H.H.); [email protected] (T.-H.T.) 2 School of Medicine, China Medical University, Taichung 40402, Taiwan; [email protected] 3 Department of Otorhinolaryngology, China Medical University Hospital, Taichung 40402, Taiwan 4 Department of Pharmacology, Chung Shan Medical University, Taichung 40201, Taiwan; [email protected] 5 Department of Pharmacy, Chung Shan Medical University Hospital, Taichung 40201, Taiwan 6 Department of Long Term Care, National Quemoy University, Kinmen 892009, Taiwan; [email protected] 7 Department of Healthcare Administration, Asia University, Taichung 41354, Taiwan 8 Department of Medical Research, China Medical University Hospital, Taichung 40402, Taiwan * Correspondence: [email protected] † These authors contributed equally to this work. Citation: Huang, K.-H.; Tai, C.-J.; Abstract: Most patients with Parkinson’s disease (PD) gradually develop oropharyngeal dysphagia Kuan, Y.-H.; Chang, Y.-C.; Tsai, T.-H.; which is often associated with pneumonia risk. The possible association of benzodiazepine (BZD) Lee, C.-Y. Pneumonia Risk Associated and benzodiazepine related drugs (BZRD) use with pneumonia risk has received increasing attention with the Use of Individual but remains controversial. We investigated pneumonia risk associated with the use of BZDs and Benzodiazepines and Benzodiazepine BZRDs in older adult patients with PD.
    [Show full text]
  • S1 Table. List of Medications Analyzed in Present Study Drug
    S1 Table. List of medications analyzed in present study Drug class Drugs Propofol, ketamine, etomidate, Barbiturate (1) (thiopental) Benzodiazepines (28) (midazolam, lorazepam, clonazepam, diazepam, chlordiazepoxide, oxazepam, potassium Sedatives clorazepate, bromazepam, clobazam, alprazolam, pinazepam, (32 drugs) nordazepam, fludiazepam, ethyl loflazepate, etizolam, clotiazepam, tofisopam, flurazepam, flunitrazepam, estazolam, triazolam, lormetazepam, temazepam, brotizolam, quazepam, loprazolam, zopiclone, zolpidem) Fentanyl, alfentanil, sufentanil, remifentanil, morphine, Opioid analgesics hydromorphone, nicomorphine, oxycodone, tramadol, (10 drugs) pethidine Acetaminophen, Non-steroidal anti-inflammatory drugs (36) (celecoxib, polmacoxib, etoricoxib, nimesulide, aceclofenac, acemetacin, amfenac, cinnoxicam, dexibuprofen, diclofenac, emorfazone, Non-opioid analgesics etodolac, fenoprofen, flufenamic acid, flurbiprofen, ibuprofen, (44 drugs) ketoprofen, ketorolac, lornoxicam, loxoprofen, mefenamiate, meloxicam, nabumetone, naproxen, oxaprozin, piroxicam, pranoprofen, proglumetacin, sulindac, talniflumate, tenoxicam, tiaprofenic acid, zaltoprofen, morniflumate, pelubiprofen, indomethacin), Anticonvulsants (7) (gabapentin, pregabalin, lamotrigine, levetiracetam, carbamazepine, valproic acid, lacosamide) Vecuronium, rocuronium bromide, cisatracurium, atracurium, Neuromuscular hexafluronium, pipecuronium bromide, doxacurium chloride, blocking agents fazadinium bromide, mivacurium chloride, (12 drugs) pancuronium, gallamine, succinylcholine
    [Show full text]
  • HS 172 R5/13 Briefly Review the Objectives, Content and Activities of This Session
    HS 172 R5/13 Briefly review the objectives, content and activities of this session. Upon successfully completing this session the participant will be able to: • Explain a brief history of the CNS Depressant category of drugs. • Identify common drug names and terms associated with this category. • Identify common methods of administration for this category. • Describe the symptoms, observable signs and other effects associated with this category. CONTENT SEGMENTS LEARNING ACTIVITIES A. Overview of the Category Instructor-Led Presentations B. Possible Effects Instructor Led Demonstrations C. OtdDtifEfftOnset and Duration of Effects RdiAiReading Assignmen ts D. Overdose Signs and Symptoms Video Presentations E. Expected Results of the Evaluation Slide Presentations F. Classification Exemplar HS 172 R5/13 9-2 • Explain the typical time parameters, i.e. onset and duration of effects, associated with this category. • List the clues that are likely to emerge when the drug influence evaluation is conducted for a person under the influence of this category of drugs. • Correctly answer the “topics for study” questions at the end of this session. HS 172 R5/13 9-3 A. Overview of the Category CNS Depressants Central Nervous System Depressants slow down the operations of the brain. Point out that other common names for CNS Depressants are “downers” and “sedative-hypnotics.” • Depressants first affect those arareaseas of the brain that control a person’ s conscious, voluntary actions. • Judgment, inhibitions and reaction time are some of the things that CNS Depressants affect first. • As the dose is increased, depressants begin to affect the parts of the brain that control the body’s automatic processes, heartbeat, respiration, etc.
    [Show full text]
  • The Emergence of New Psychoactive Substance (NPS) Benzodiazepines
    Issue: Ir Med J; Vol 112; No. 7; P970 The Emergence of New Psychoactive Substance (NPS) Benzodiazepines. A Survey of their Prevalence in Opioid Substitution Patients using LC-MS S. Mc Namara, S. Stokes, J. Nolan HSE National Drug Treatment Centre Abstract Benzodiazepines have a wide range of clinical uses being among the most commonly prescribed medicines globally. The EU Early Warning System on new psychoactive substances (NPS) has over recent years detected new illicit benzodiazepines in Europe’s drug market1. Additional reference standards were obtained and a multi-residue LC- MS method was developed to test for 31 benzodiazepines or metabolites in urine including some new benzodiazepines which have been classified as New Psychoactive Substances (NPS) which comprise a range of substances, including synthetic cannabinoids, opioids, cathinones and benzodiazepines not covered by international drug controls. 200 urine samples from patients attending the HSE National Drug Treatment Centre (NDTC) who are monitored on a regular basis for drug and alcohol use and which tested positive for benzodiazepine class drugs by immunoassay screening were subjected to confirmatory analysis to determine what Benzodiazepine drugs were present and to see if etizolam or other new benzodiazepines are being used in the addiction population currently. Benzodiazepine prescription and use is common in the addiction population. Of significance we found evidence of consumption of an illicit new psychoactive benzodiazepine, Etizolam. Introduction Benzodiazepines are useful in the short-term treatment of anxiety and insomnia, and in managing alcohol withdrawal. 1 According to the EMCDDA report on the misuse of benzodiazepines among high-risk opioid users in Europe1, benzodiazepines, especially when injected, can prolong the intensity and duration of opioid effects.
    [Show full text]
  • House Bill No.11 (2019)
    LEGISLATURE OF THE STATE OF IDAHO Sixty-fifth Legislature First Regular Session - 2019 IN THE HOUSE OF REPRESENTATIVES HOUSE BILL NO. 11 BY HEALTH AND WELFARE COMMITTEE 1 AN ACT 2 RELATING TO CONTROLLED SUBSTANCES; AMENDING SECTION 37-2705, IDAHO CODE, TO 3 REVISE THE LIST OF SCHEDULE I CONTROLLED SUBSTANCES; AMENDING SECTION 4 37-2709, IDAHO CODE, TO PROVIDE AN EXCLUSION AND TO MAKE A TECHNICAL 5 CORRECTION; AMENDING SECTION 37-2713, IDAHO CODE, TO REVISE THE LIST OF 6 SCHEDULE V DRUGS AND SUBSTANCES; AND DECLARING AN EMERGENCY. 7 Be It Enacted by the Legislature of the State of Idaho: 8 SECTION 1. That Section 37-2705, Idaho Code, be, and the same is hereby 9 amended to read as follows: 10 37-2705. SCHEDULE I. (a) The controlled substances listed in this sec- 11 tion are included in schedule I. 12 (b) Any of the following opiates, including their isomers, esters, 13 ethers, salts, and salts of isomers, esters, and ethers, unless specifically 14 excepted, whenever the existence of these isomers, esters, ethers and salts 15 is possible within the specific chemical designation: 16 (1) Acetyl-alpha-methylfentanyl (N-[1-(1-methyl-2-phenethyl)-4-pip- 17 eridinyl]-N-phenylacetamide); 18 (2) Acetylmethadol; 19 (3) Acetyl fentanyl (N-(1-phenethylpiperidin-4-yl)-N-phenylac- 20 etamide); 21 (4) Allylprodine; 22 (5) Alphacetylmethadol (except levo-alphacetylmethadol also known as 23 levo-alpha-acetylmethadol, levomethadyl acetate or LAAM); 24 (6) Alphameprodine; 25 (7) Alphamethadol; 26 (8) Alpha-methylfentanyl; 27 (9) Alpha-methylthiofentanyl
    [Show full text]
  • A New Colorimetric Identification of Benzodiazepines: Using Cobalt Thiocyanate As Reagent
    Applied f Ph l o a r a m n r a u c Mahmood et al., J Appl Pharm 2018, 10:3 o y J Journal of Applied Pharmacy DOI: 10.4172/1920-4159.1000265 ISSN: 1920-4159 Research Article Article OpenOpen Access Access A New Colorimetric Identification of Benzodiazepines: Using Cobalt Thiocyanate as Reagent Mahmood Z1*, Muhammad S2, Arshad N3, Tahir MA1, Qurashi MZ3 and Usman M1 1Narcotics Unit, Punjab Forensic Science Agency, Lahore, Punjab, Pakistan 2Consultant Toxicology and Narcotics Unit, Punjab Forensic Science Agency, Lahore, Pakistan 3Chemistry Department, Govt College University, Lahore, Punjab, Pakistan Abstract A highly specific, easy to perform and cost effective color test for benzodiazepines class has been developed. This colour test produced green colour with eight benzodiazepines i.e. nitrazepam, temazepam, diazepam, bromazepam, clonazepam, estazolam, lormetazolam and alprazolam, whereas developed color was absent in other controlled or pharmaceutical substances tested during study. In this color test, one drop of concentrated hydrochloric acid was added to test substrate. Then two drops of cobalt thiocyante reagent were added in subsequently which resulted in an immediate appearance of green color. So this test can be very helpful as a presumptive screening tool for benzodiazepines testing in suspected illicit samples and pharmaceuticals. Moreover, this test can be further employed for diazepam quantitation using ultraviolet spectroscopy at 364 nm wavelength and showed linear detector response. A regression co-efficient value of 0.9996 was achieved using developed method and was effectively useful for diazepam quantitation in pharmaceutical dosage forms. Keywords: Presumptive color testing; Benzodiazepine analysis; economical and has reasonable sensitivity towards tested benzos.
    [Show full text]
  • Pharmaceuticals As Environmental Contaminants
    PharmaceuticalsPharmaceuticals asas EnvironmentalEnvironmental Contaminants:Contaminants: anan OverviewOverview ofof thethe ScienceScience Christian G. Daughton, Ph.D. Chief, Environmental Chemistry Branch Environmental Sciences Division National Exposure Research Laboratory Office of Research and Development Environmental Protection Agency Las Vegas, Nevada 89119 [email protected] Office of Research and Development National Exposure Research Laboratory, Environmental Sciences Division, Las Vegas, Nevada Why and how do drugs contaminate the environment? What might it all mean? How do we prevent it? Office of Research and Development National Exposure Research Laboratory, Environmental Sciences Division, Las Vegas, Nevada This talk presents only a cursory overview of some of the many science issues surrounding the topic of pharmaceuticals as environmental contaminants Office of Research and Development National Exposure Research Laboratory, Environmental Sciences Division, Las Vegas, Nevada A Clarification We sometimes loosely (but incorrectly) refer to drugs, medicines, medications, or pharmaceuticals as being the substances that contaminant the environment. The actual environmental contaminants, however, are the active pharmaceutical ingredients – APIs. These terms are all often used interchangeably Office of Research and Development National Exposure Research Laboratory, Environmental Sciences Division, Las Vegas, Nevada Office of Research and Development Available: http://www.epa.gov/nerlesd1/chemistry/pharma/image/drawing.pdfNational
    [Show full text]